SUVEN Life Sciences

Communication to investors
Mar 2015

26-May-15

2014-15 Q4 results

Risk statement
Except for historical information, all of the statements, expectations
and assumptions, including expectations and assumptions,
contained in this presentation may be forward-looking statements
that involve a number of risks and uncertainties. Although Suven
attempts to be accurate in making these forward-looking statements,
it is possible that future circumstances might differ from the
assumptions on which such statements are based. Other important
factors which could cause these statements to differ materially
including outsourcing trends, economic conditions, dependence on
collaborative partnership programs, retention of key personnel,
technological advances and continued success in growth of sales
that may make our products/services offerings less competitive;
Suven may not undertake to update any forward-looking statements
that may be made from time to time.
26-May-15

2014-15 Q4 results

FINANCIAL QUICK VIEW

Quarter 4 Mar 2015

Growth in revenue
Growth in PAT
Growth in EBIDTA
Growth in Pre-R&D EBIDTA
Increase in R&D costs
R&D cost on revenue

26-May-15

2014-15 Q4 results

-13.28%
-47.70%
-45.46%
-31.13%
25.18%
13.54%

FINANCIAL QUICK VIEW

Year ending Mar 2015

Growth in revenue
Growth in PAT
Growth in EBIDTA
Growth in Pre-R&D EBIDTA
Increase in R&D costs
R&D cost on revenue

26-May-15

2014-15 Q4 results

3.14%
-24.56%
-24.34%
-17.05%
16.72%
10.57%

MAJOR PROFITABILITY RATIOS

26-May-15

Q4 Mar 15

YE Mar 15

PAT to
Income

14.81%

20.54%

EBIDTA to
Income

23.17%

31.74%

Cash Flow to
Income

17.14%

22.76%

Pre-R&D
EBITDA to
Income

36.71%

42.31%

2014-15 Q4 results

INCOME COMPARISON
6200
5133.42

Rupees Million

5200

5294.36

4200
3200
2200
1320.06

1200

1144.73

200
Qtr Mar14
26-May-15

Qtr Mar15

YE Mar14

2014-15 Q4 results

YE Mar15

PROFIT COMPARISON
1600

1441.58

Rupees Million

1400
1200

1087.5

1000
800
600
400

324.06
169.49

200
0
Qtr Mar14

26-May-15

Qtr Mar15

YE Mar14

2014-15 Q4 results

YE Mar15

EBIDTA COMPARISON
2500
2220.88

RupeesMillion

2000
1680.4

1500
1000
500

486.4
265.28

0
Qtr Mar14 Qtr Mar15 YE Mar14 YE Mar15
26-May-15

2014-15 Q4 results

Rupees Million

R & D EXPENDITURE
500
450
400
350
300
250
200
150
100
50

346.93

559.63

154.98
123.81

Qtr Mar14 Qtr Mar15 YE Mar14 YE Mar15

26-May-15

2014-15 Q4 results

PRE-R&D EBIDTA
3000

2700.36

Rupees Million

2500

2240.02

2000
1500
1000
610.20

500

420.26

0
Qtr Mar14 Qtr Mar15 YE Mar14 YE Mar15
26-May-15

2014-15 Q4 results

PRE-R&D CASHFLOW
2009.43

2000

1648.38

Rupees Million

1600
1200
800
470.61

400

329.89

0
Qtr Mar14 Qtr Mar15 YE Mar14 YE Mar15
26-May-15

2014-15 Q4 results

Updates for the quarter

Suven has 743 product patents for 26 inventions and 37 process
patents for 7 inventions
SUVN-502 completed phase 1b clinical trial in USA is in preparation
for Phase 2a (POC) study on patients in USA
SUVN G-3031 undergoing phase 1 clinical trial in USA
SUVN D-4010 undergoing IND enabling toxicological studies in USA
in preparation for Phase 1 clinical trial.
Number of active CRAMS projects - 110
The Board has proposed a Dividend of Re.0.60 per share (60% of
face value Rs. 1.00 each) for the financial year 2014-15, subject to
approval of the shareholders in the ensuing Annual General
Meeting.

26-May-15

2014-15 Q4 results